

US Therapeutic Plasma Exchange Market by Product (Devices, Consumables) Technology (Centrifugation, Membrane Separation) Procedures & Patients (Guillain Syndrome, Multiple Sclerosis, Cryoglobulinemia) End Users Covid-19 Impact - Forecast to 2025

<https://marketpublishers.com/r/UDB22C5786AEN.html>

Date: September 2020

Pages: 122

Price: US\$ 4,950.00 (Single User License)

ID: UDB22C5786AEN

Abstracts

The US therapeutic plasma exchange market is projected to reach USD 243 million by 2025 from USD 178 million in 2020, at a CAGR of 6.3% during the forecast period. Growth in this market is driven by the rising prevalence of chronic diseases and technological advancements. However, factors such as the high cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model are expected to restrain the growth of this market to a certain extent during the forecast period.

“The consumables segment to grow at the highest rate during the forecast period.”

On the basis of products, the US therapeutic plasma exchange market has been segmented into devices and consumables. The consumables segment witness the highest growth during the forecast period. The large share of this segment can be attributed to the recurrent use of these products, the increasing number of therapeutic plasma exchange procedures, and favorable reimbursement policies for TPE procedures.

“Advantages offered by centrifugation over membrane separation are driving market growth for centrifugation.”

On the basis of technology, the US therapeutic plasma exchange market has been segmented into centrifugation and membrane separation. In 2019, the centrifugation technology segment accounted for the largest share of the US therapeutic plasma exchange market. The large share of this segment can be attributed to the advantages offered by centrifugation over membrane separation, such as high efficiency and its ability to separate all types of blood components.

“Blood collection centers and blood component providers accounted for the largest share of the end user market “

On the basis of end user, the US therapeutic plasma exchange market has been segmented into blood

collection centers and blood component providers, hospitals and transfusion centers, and other end users. In 2019, the blood collection centers and blood component providers segment accounted for the largest share of the US therapeutic plasma exchange market. The large share of this end-user segment is mainly attributed to the rising number of blood component donations, the growing number of blood centers, and the increasing number of therapeutic plasma exchange procedures and plasma donations due to COVID-19.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1–30%, Tier 2–45%, and Tier 3–25%

By Designation: C-level–35%, Director Level–25%, and Others–40%

The prominent players in the US therapeutic plasma exchange market include Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Miltenyi Biotec (Germany), Medica S.p.A. (Italy), Medicap Clinic GmbH (Germany), and Infomed (Switzerland).

Research Coverage:

The report analyzes the market for various US therapeutic plasma exchange and their

adoption pattern. It aims at estimating the market size and future growth potential of the US therapeutic plasma exchange market and different segments such as products, end user, and regions. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios offered by the top players in the US therapeutic plasma exchange market

Product & Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the US therapeutic plasma exchange market

Market Development: Comprehensive information on the lucrative emerging regions by products, technology, indication, and end user

Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the US therapeutic plasma exchange market

Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products & services of leading players in the US therapeutic plasma exchange market

Contents

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS AND EXCLUSIONS

1.3 MARKET SCOPE

1.3.1 MARKETS COVERED

1.3.2 YEARS CONSIDERED FOR THE STUDY

1.4 CURRENCY

TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD

1.5 LIMITATIONS

1.6 STAKEHOLDERS

1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

FIGURE 1 RESEARCH DESIGN

2.1.1 SECONDARY DATA

2.1.1.1 Key data from secondary sources

2.1.2 PRIMARY DATA

FIGURE 2 PRIMARY SOURCES

2.1.2.1 Key data from primary sources

2.1.2.2 Breakdown of primary interviews

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE AND DESIGNATION

2.2 MARKET SIZE ESTIMATION

FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS

FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (ILLUSTRATIVE EXAMPLE)

FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH

2.3 MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 7 DATA TRIANGULATION METHODOLOGY

2.4 MARKET SHARE ESTIMATION

2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

FIGURE 8 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)

FIGURE 9 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY TECHNOLOGY, 2020 VS. 2025 (USD MILLION)

FIGURE 10 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY INDICATION, 2020 VS. 2025 (USD MILLION)

FIGURE 11 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)

4 MARKET OVERVIEW

4.1 INTRODUCTION

4.2 MARKET DYNAMICS

FIGURE 12 US THERAPEUTIC PLASMA EXCHANGE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

4.2.1 DRIVERS

4.2.1.1 Rising prevalence of chronic diseases

4.2.1.2 Technological advancements

4.2.2 RESTRAINTS

4.2.2.1 High cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model

4.2.3 OPPORTUNITIES

4.2.3.1 Therapeutic plasma exchange for pediatric patients

4.2.4 CHALLENGES

4.2.4.1 Dearth of skilled professionals

5 INDUSTRY INSIGHTS

5.1 INDUSTRY TRENDS

5.1.1 IMPACT OF COVID-19 ON THE THERAPEUTIC PLASMA EXCHANGE MARKET

FIGURE 13 IMPACT OF COVID-19 (2020-2025)

5.1.2 NEW INDICATIONS FOR PLASMA PRODUCTS

5.2 PORTER'S FIVE FORCES ANALYSIS

FIGURE 14 PORTER'S FIVE FORCES ANALYSIS (2019): US THERAPEUTIC PLASMA EXCHANGE MARKET

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 THREAT OF SUBSTITUTES

5.2.3 BARGAINING POWER OF SUPPLIERS

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 RIVALRY AMONG EXISTING COMPETITORS

5.3 VALUE CHAIN ANALYSIS

FIGURE 15 VALUE CHAIN: US THERAPEUTIC PLASMA EXCHANGE MARKET

5.4 REGULATORY ANALYSIS

5.4.1 US

6 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT & TECHNOLOGY

6.1 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT

6.1.1 INTRODUCTION

TABLE 2 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY PRODUCT, 2018–2025 (USD MILLION)

6.1.2 CONSUMABLES

6.1.2.1 Recurrent use of consumables to drive the growth of this segment

6.1.3 DEVICES

6.1.3.1 Increasing installation of devices in hospitals for therapeutic plasma exchange to drive market growth

6.2 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY TECHNOLOGY

6.2.1 INTRODUCTION

TABLE 3 CENTRIFUGATION VS. MEMBRANE SEPARATION

FIGURE 16 CENTRIFUGATION SEGMENT TO DOMINATE THE US THERAPEUTIC PLASMA EXCHANGE MARKET DURING THE FORECAST PERIOD

TABLE 4 THERAPEUTIC PLASMA EXCHANGE MARKET, BY TECHNOLOGY, 2018–2025 (USD MILLION)

6.2.2 CENTRIFUGATION

6.2.2.1 Centrifugation technology to dominate the US therapeutic plasma exchange market

TABLE 5 KEY PRODUCTS OFFERED IN THE CENTRIFUGATION MARKET

6.2.3 MEMBRANE SEPARATION

6.2.3.1 Recent advances in developing highly permeable filters are supporting the growth of this market

TABLE 6 SIZE OF BLOOD COMPONENTS

TABLE 7 MEMBRANE SEPARATION PRODUCTS AVAILABLE IN THE MARKET

7 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY INDICATION

7.1 INTRODUCTION

7.2 NEUROLOGICAL DISORDERS

7.2.1 NEUROLOGICAL DISORDERS ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2019

TABLE 8 NEUROLOGICAL DISORDERS MARKET, BY TYPE, 2018–2025 (USD MILLION)

7.2.1.1 Guillain–Barré syndrome

7.2.1.1.1 Patient and procedure data for guillain-barré syndrome

TABLE 9 DISEASE STATISTICS: GUILLAIN-BARRÉ SYNDROME

TABLE 10 TREATMENT GUIDELINES AND PROTOCOLS FOR GUILLAIN-BARRÉ SYNDROME

TABLE 11 EPIDEMIOLOGY FOR GUILLAIN-BARRÉ SYNDROME

7.2.1.2 Chronic inflammatory demyelinating polyneuropathy

7.2.1.2.1 Patient and procedure data for chronic inflammatory demyelinating polyneuropathy

TABLE 12 DISEASE STATISTICS: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

TABLE 13 TREATMENT GUIDELINES AND PROTOCOLS FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

TABLE 14 EPIDEMIOLOGY FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

7.2.1.3 Myasthenia gravis

7.2.1.3.1 Patient and procedure data for myasthenia gravis

TABLE 15 DISEASE STATISTICS: MYASTHENIA GRAVIS

TABLE 16 TREATMENT GUIDELINES AND PROTOCOLS FOR MYASTHENIA GRAVIS

TABLE 17 EPIDEMIOLOGY FOR MYASTHENIA GRAVIS

7.2.1.4 Multiple sclerosis

7.2.1.4.1 Patient and procedure data for multiple sclerosis

TABLE 18 DISEASE STATISTICS: MULTIPLE SCLEROSIS

TABLE 19 TREATMENT GUIDELINES AND PROTOCOLS FOR MULTIPLE SCLEROSIS

TABLE 20 TREATMENT GUIDELINES AND PROTOCOLS FOR CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS

TABLE 21 EPIDEMIOLOGY FOR MULTIPLE SCLEROSIS

7.2.1.5 PANDAS

7.2.1.5.1 Patient and procedure data for PANDAS

TABLE 22 DISEASE STATISTICS: PANDAS

TABLE 23 TREATMENT GUIDELINES AND PROTOCOLS FOR PANDAS

TABLE 24 EPIDEMIOLOGY FOR PANDAS

7.3 HEMATOLOGIC DISORDERS

7.3.1 INCREASING PREVALENCE AND INCIDENCE OF HEMATOLOGIC DISORDERS WILL BOOST THE DEMAND FOR THERAPEUTIC PLASMA EXCHANGE

TABLE 25 HEMATOLOGIC DISORDERS MARKET, BY TYPE, 2018–2025 (USD MILLION)

7.3.1.1 Thrombotic thrombocytopenic purpura

7.3.1.1.1 Patient and procedure data for thrombotic thrombocytopenic purpura

TABLE 26 DISEASE STATISTICS: THROMBOTIC THROMBOCYTOPENIC PURPURA

TABLE 27 TREATMENT GUIDELINES AND PROTOCOLS FOR THROMBOTIC THROMBOCYTOPENIC PURPURA

TABLE 28 EPIDEMIOLOGY FOR THROMBOTIC THROMBOCYTOPENIC PURPURA

7.3.1.2 Atypical hemolytic uremic syndrome

7.3.1.2.1 Patient and procedure data for atypical hemolytic uremic syndrome

TABLE 29 DISEASE STATISTICS: ATYPICAL HEMOLYTIC UREMIC SYNDROME

TABLE 30 TREATMENT GUIDELINES AND PROTOCOL FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME

TABLE 31 EPIDEMIOLOGY FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME

7.3.1.3 Hyperviscosity syndrome

7.3.1.3.1 Patient and procedure data for hyperviscosity syndrome

TABLE 32 DISEASE STATISTICS: HYPERVISCOSITY SYNDROME

TABLE 33 TREATMENT GUIDELINES AND PROTOCOLS FOR HYPERVISCOSITY SYNDROME

TABLE 34 EPIDEMIOLOGY FOR HYPERVISCOSITY SYNDROME

7.3.1.4 Severe/symptomatic cryoglobulinemia

7.3.1.4.1 Patient and procedure data for cryoglobulinemia

TABLE 35 DISEASE STATISTICS: CRYOGLOBULINEMIA

TABLE 36 TREATMENT GUIDELINES AND PROTOCOLS FOR CRYOGLOBULINEMIA

TABLE 37 EPIDEMIOLOGY FOR CRYOGLOBULINEMIA

7.4 RENAL DISORDERS

7.4.1 THERAPEUTIC PLASMA EXCHANGE IS REGARDED AS ONE OF THE MOST USEFUL TREATMENT OPTIONS FOR SEVERAL RENAL DISORDERS

TABLE 38 RENAL DISORDERS MARKET, BY TYPE, 2018–2025 (USD MILLION)

7.4.1.1 Goodpasture syndrome

7.4.1.1.1 Patient and procedure data for goodpasture syndrome

TABLE 39 DISEASE STATISTICS: GOODPASTURE SYNDROME

TABLE 40 TREATMENT GUIDELINES AND PROTOCOLS FOR GOODPASTURE

SYNDROME

TABLE 41 EPIDEMIOLOGY FOR GOODPASTURE SYNDROME

7.4.1.2 WEGENER'S GRANULOMATOSIS (ANCA)-associated rapidly progressive glomerulonephritis

7.4.1.2.1 Patient and procedure data for wegener's granulomatosis

TABLE 42 DISEASE STATISTICS: WEGENER'S GRANULOMATOSIS

TABLE 43 TREATMENT GUIDELINES AND PROTOCOLS FOR WEGENER'S GRANULOMATOSIS

TABLE 44 EPIDEMIOLOGY FOR WEGENER'S GRANULOMATOSIS

7.4.1.3 Antibody-mediated renal transplant rejection

7.4.1.3.1 Patient and procedure data for AMR

TABLE 45 DISEASE STATISTICS: ANTIBODY-MEDIATED REJECTION

TABLE 46 TREATMENT GUIDELINES AND PROTOCOLS FOR ANTIBODY-MEDIATED REJECTION

TABLE 47 EPIDEMIOLOGY FOR ANTIBODY-MEDIATED REJECTION

7.5 METABOLIC DISORDERS

7.5.1 INCREASING ADOPTION OF PLASMA EXCHANGE FOR DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE MARKET GROWTH

7.5.1.1 Familial hypercholesterolemia (homozygous)

7.5.1.1.1 Patient and procedure data for homozygous familial hypercholesterolemia

TABLE 48 DISEASE STATISTICS: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

TABLE 49 TREATMENT GUIDELINES AND PROTOCOLS FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

TABLE 50 EPIDEMIOLOGY FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

7.6 OTHER INDICATIONS

8 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER

8.1 INTRODUCTION

FIGURE 17 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS SEGMENT TO DOMINATE THE US THERAPEUTIC PLASMA EXCHANGE MARKET DURING THE FORECAST PERIOD

TABLE 51 US THERAPEUTIC PLASMA EXCHANGE MARKET, BY END USER, 2018–2025 (USD MILLION)

8.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS

8.2.1 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS ARE THE LARGEST END USERS OF THERAPEUTIC PLASMA EXCHANGE

FIGURE 18 NUMBER OF ANNUAL PLASMA DONATIONS IN THE US, 2003-2016
(MILLION)

8.3 HOSPITALS & TRANSFUSION CENTERS

8.3.1 HOSPITALS & TRANSFUSION CENTERS SEGMENT TO REGISTER THE
HIGHEST CAGR DURING THE FORECAST PERIOD

8.4 OTHER END USERS

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW

FIGURE 19 KEY DEVELOPMENTS IN THE US THERAPEUTIC PLASMA EXCHANGE
MARKET, JANUARY 2017-JULY 2020

9.2 MARKET EVALUATION FRAMEWORK

FIGURE 20 MARKET EVALUATION FRAMEWORK: PRODUCT LAUNCHES &
APPROVALS WERE THE MOST WIDELY ADOPTED STRATEGIES

9.3 COMPETITIVE SITUATIONS AND TRENDS

9.3.1 PRODUCT LAUNCHES & APPROVALS

9.3.2 EXPANSIONS

9.3.3 ACQUISITIONS

9.3.4 COLLABORATIONS

10 COMPANY EVALUATION MATRIX AND COMPANY PROFILES

10.1 COMPANY EVALUATION MATRIX DEFINITION & METHODOLOGY

10.2 COMPETITIVE LEADERSHIP MAPPING

10.2.1 STARS

10.2.2 EMERGING LEADERS

10.2.3 PERVASIVE

10.2.4 EMERGING COMPANIES

FIGURE 21 US THERAPEUTIC PLASMA EXCHANGE MARKET: COMPETITIVE
LEADERSHIP MAPPING (2019)

10.3 MARKET SHARE ANALYSIS

FIGURE 22 US THERAPEUTIC PLASMA EXCHANGE MARKET SHARE, BY KEY
PLAYER, 2019

10.4 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, Strategic overview,
Competitive analysis, MnM View)*

10.4.1 TERUMO BCT, INC.

FIGURE 23 TERUMO BCT, INC.: COMPANY SNAPSHOT (2018)

10.4.2 FRESENIUS SE & CO. KGAA

FIGURE 24 FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT (2019)

FIGURE 25 FRESENIUS KABI: COMPANY SNAPSHOT (2019)

10.4.3 HAEMONETICS CORPORATION

FIGURE 26 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2020)

10.4.4 BAXTER INTERNATIONAL INC.

FIGURE 27 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2019)

10.4.5 ASAHI KASEI MEDICAL CO. LTD.

FIGURE 28 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2019)

10.4.6 B. BRAUN MELSUNGEN AG

FIGURE 29 B. BRAUN MELSUNGEN: COMPANY SNAPSHOT (2019)

10.4.7 CERUS CORPORATION

FIGURE 30 CERUS CORPORATION: COMPANY SNAPSHOT (2019)

10.4.8 KANEKA CORPORATION

FIGURE 31 KANEKA CORPORATION: COMPANY SNAPSHOT (2019)

10.4.9 KAWASUMI LABORATORIES, INC.

FIGURE 32 KAWASUMI LABORATORIES: COMPANY SNAPSHOT (2019)

10.4.10 NIKKISO CO., LTD.

FIGURE 33 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2019)

10.4.11 MILTENYI BIOTEC

10.4.12 MEDICA S.P.A.

10.4.13 MEDICAP CLINIC GMBH

10.4.14 INFOMED

*Business Overview, Products Offered, Recent Developments, Strategic overview, Competitive analysis, MnM View might not be captured in case of unlisted companies.

11 APPENDIX

11.1 INSIGHTS OF INDUSTRY EXPERTS

11.2 DISCUSSION GUIDE

11.3 KNOWLEDGE STORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

11.4 AVAILABLE CUSTOMIZATIONS

11.5 RELATED REPORTS

11.6 AUTHOR DETAILS

I would like to order

Product name: US Therapeutic Plasma Exchange Market by Product (Devices, Consumables) Technology (Centrifugation, Membrane Separation) Procedures & Patients (Guillain Syndrome, Multiple Sclerosis, Cryoglobulinemia) End Users Covid-19 Impact - Forecast to 2025

Product link: <https://marketpublishers.com/r/UDB22C5786AEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UDB22C5786AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970